Filing identity and reporting period
Important metadata discrepancy: The supplied filing is Ruthigen, Inc.’s Form 10-Q, not a Pulmatrix, Inc. filing. It covers the quarter and six months ended September 30, 2014; the financial statements are unaudited.
Ruthigen was a pre-revenue biopharmaceutical company developing RUT58-60, a hypochlorous-acid-based candidate for preventing and treating infections associated with surgery and trauma. Its initial clinical focus was abdominal surgery.
Financial results and position
| Metric | Three months ended Sept. 30, 2014 | Six months ended Sept. 30, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development | $629,000 | $1.305 million | $495,000 and $670,000, respectively |
| Selling, general and administrative | $1.086 million | $2.129 million | $499,000 and $801,000, respectively |
| Total operating expenses | $1.715 million | $3.434 million | $994,000 and $1.471 million, respectively |
| Net loss | $1.710 million | $3.425 million | $994,000 and $1.471 million, respectively |
| Net loss per share, basic and diluted | $0.35 | $0.72 | $0.50 and $0.74, respectively |
- Cash and liquidity: Cash was $12.880 million at September 30, 2014, down from $15.571 million at March 31, 2014. Working capital was $12.594 million, versus $14.627 million. Management said existing cash was expected to fund operations through the quarter ending December 31, 2015.
- Cash flows, six months: Operating activities used $2.918 million; investing activities used $103,000; financing activities provided $330,000. Cash decreased by $2.691 million.
- Capital and liabilities: Total assets were $13.274 million and current liabilities were $575,000. The balance sheet lists no debt; it shows $573,000 in accounts payable and accrued expenses and $2,000 payable to the former parent.
- Margins: Not meaningful because the company had no revenue.
Changes versus comparable periods
- For the six months, operating expenses more than doubled year over year: R&D rose 95% and SG&A rose 166%. Management attributed the increases principally to RUT58-60 development and clinical-trial preparation, public-company legal, accounting and insurance costs, and stock-based compensation.
- Six-month net loss increased to $3.425 million from $1.471 million; six-month operating cash use increased to $2.918 million from $1.357 million.
- Cash fell from March 31, 2014, despite $865,000 of net IPO proceeds received during the six-month period. The company also repaid $535,000 of advances from its former parent.
- Common shares outstanding rose from 4.650 million at March 31 to 4.804 million at September 30. The period included a partial underwriter overallotment exercise that generated approximately $1.028 million net proceeds.
Outlook, risks, and notable items
- Management expected R&D and administrative expenses to continue increasing and estimated approximately $50 million in total operating expense to bring RUT58-60 through its goal of FDA approval. This was an estimate, not a committed budget or assurance of approval.
- The company said it would need additional funding to execute its development strategy and pursue regulatory approvals. It had no financing commitment and warned that unavailable or unacceptable financing could force reductions in R&D and other activities. Equity financing could dilute shareholders; debt or collaboration financing could impose restrictions or require rights concessions.
- The IND became effective in June 2014. The company reported completing a 21-day skin-irritation trial in August. After quarter-end, it initiated a Phase 1/2 trial in October and began enrollment in November, initially planning a 20-patient safety run-in subject to data monitoring committee review.
- The license and supply agreement with Oculus provides exclusive rights in specified territories and indications. It may require up to $8 million in milestone payments; none had been accrued at September 30 because achievement was not then considered probable.
- Potential cash severance under CEO and CFO employment agreements totaled $1.144 million at September 30. The filing reported no material legal proceedings and no material changes to previously disclosed risk factors.
- Stock-based compensation was $467,000 for the six months. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the source filing identifies Ruthigen, Inc., whereas the request metadata names Pulmatrix, Inc.
- Review subsequent clinical-trial progress, safety findings, enrollment, and data monitoring committee decisions.
- Assess cash burn against the stated runway through December 2015 and the estimated $50 million development cost, including the availability and terms of additional financing.
- Check the timing and conditions of potential Oculus milestone payments, and the impact of equity awards, warrants, and any future share issuance.
- Evaluate the assumptions and uncertainty behind FDA approval, commercialization, and any prospective collaboration; the filing provides no assurance of success.